Dinas Konstantinos, Pratilas Georgios C, Nasioutziki Maria, Vavoulidis Eleftherios, Makris Vasileios, Loufopoulos Panagiotis D, Kalder Matthias
Second Department of Obstetrics and Gynecology, Aristotle University, Thessaloniki, Ippokrateio Hospital of Thessaloniki, Greece.
First Department of General Surgery, School of Medicine, Aristotle University, Thessaloniki, Papageorgiou Hospital of Thessaloniki, Greece.
Folia Med (Plovdiv). 2018 Sep 1;60(3):364-372. doi: 10.2478/folmed-2018-0002.
Fine needle aspiration cytology (FNAC) has been and still is challenged about its role in the management of breast lesions. Guidelines today mandate that breast lesions should be managed with a triple assessment system consisting of clinical, radiological, and pathological evaluation.
This article will try and clarify whether FNAC stands as a tool in this assessment.
PubMed was searched for articles concerning prospective, retrospective and review studies about clinical applications of FNAC.
Specialists agree and evidence occurs that FNAC could be the examination of first choice in matters of pathological evaluation.
It is an easily performed, patient-friendly and cheap examination. It can successfully and quite quickly filter out benign breast conditions without any further cost or stress to the patient. In cases with inconclusive results or insufficient samples it should be followed by needle core biopsy (NCB). As a method, it has its limitations. It cannot directly provide information about tissue architecture, and identify certain breast conditions. Modern developments in liquid based cytology (LBC) upgrade its role in neoadjuvant chemotherapy too. In order to have satisfactory results, high levels of experience are required.
细针穿刺细胞学检查（FNAC）在乳腺病变管理中的作用一直且仍面临挑战。如今的指南规定，乳腺病变应采用由临床、放射学和病理学评估组成的三重评估系统进行管理。
本文将试图阐明FNAC在这一评估中是否可作为一种工具。
在PubMed上检索有关FNAC临床应用的前瞻性、回顾性和综述性研究的文章。
专家们达成共识且有证据表明，在病理学评估方面，FNAC可能是首选检查方法。
它是一种操作简便、对患者友好且成本低廉的检查。它能够成功且相当迅速地筛除非乳腺病变，而不会给患者带来任何额外费用或压力。在结果不明确或样本不足的情况下，应接着进行粗针活检（NCB）。作为一种方法，它有其局限性。它不能直接提供有关组织结构的信息，也无法识别某些乳腺病变。液基细胞学（LBC）的现代发展也提升了其在新辅助化疗中的作用。为了获得满意的结果，需要高水平的经验。
